Key facts
- This page summarizes Mitchell Chan's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Dec 2023, 16:01.
Mitchell Chan - 20 Dec 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)
- Reporting relationship
- Director
- Issuer ticker
- AVTX
- Reported as of
- 20 Dec 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Dec 2023, 16:01:43 UTC
- Prior SEC filing
- 15 Jun 2022
- Next SEC filing
- 14 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Zoltoski, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mitchell Chan filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 21 Dec 2023.
Change
- Previous filing in this sequence was filed on 15 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +3,334
- Change %
- Price
- $0.000000
- Shares after
- 3,334
- Date
- 20 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,334
- Exercise price
- $0.0430
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option will vest in full on December 20, 2024, subject to the Reporting Person's continued service on such vesting date.